Clinical Trials
9 trialsNCT05470491 2026-06-03
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT04721301 2023-10-17
Ipilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer the LUMINESCENCE Trial
University Hospital Heidelberg
Phase 1 Completed
NCT03274804 2022-06-07
PICCASSO
University Hospital Heidelberg
Phase 1 Completed
NCT01276236 2021-03-05
Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS)
University of California, San Francisco
Phase 2 Completed
NCT01785810 2021-01-11
Phase II Maraviroc for GVHD Prevention
Abramson Cancer Center at Penn Medicine
Phase 2 Completed
NCT02208037 2019-01-23
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)
National Heart, Lung, and Blood Institute (NHLBI)
Phase 2 Completed
NCT01736813 2017-03-22
MARACON
National Center for Tumor Diseases, Heidelberg
Completed
NCT02799888 2016-06-15
Maraviroc-Based GVHD Prophylaxis in HLA-Unrelated and HLA-Mismatched Related Transplantation
Affiliated Hospital to Academy of Military Medical Sciences
Phase 2 Unknown
NCT01329783 2011-05-16
EuroSIDA As An External Comparator To MOTIVATE Trials
ViiV Healthcare
Completed